Editas Medicine Is A Gene Editing Company Founded In 2013 And Based In Cambridgemassachusettswith An Additional Location In Bouldercoloradothe Company Focuses On Developing Innovative Medicines Using Crispr Cas9 And Crispr Cas12A Technologies To Treat Serious Diseaseseditas Medicine Aims To Create A Robust Pipeline Of Genomic Medicines That Can Significantly Improve The Lives Of Individuals With Severe Conditions The Company Offers Gene Editing Technologies And Methodologiesincluding Its Product Edit 301Reni Cel An Ex Vivo Gene Edited Cell Therapy Designed For Patients With Severe Sickle Cell Disease And Transfusion Dependent Beta Thalassemiaeditas Medicine Is Also Engaged In Ongoing Research And Development Of Therapies Targeting Various Genetic Diseasesincluding Eye Diseases And Cancerthe Company Collaborates With Partners Like Bristol Myers Squibbimmatics N V And Allergan To Advance Its Therapeutic Assets And Expand Its Impact In The Field Of Genomic Medicine
